SAN DIEGO, CA -- (MARKET WIRE) -- 12/14/06 -- Founder and CEO Marc Pilkington of Tulip BioMed(TM), Inc. (PINKSHEETS: TPBD), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, has been identified by Inc. Magazine as one of the top 13 "Reader Favorites" in its Entrepreneur of the Year contest announced this week.

Pilkington was selected for starting a company that is focused on providing safer instruments for liposuction, fat transfer and other micro-surgeries. The minimally invasive disposable instruments developed by Tulip BioMed are designed to solve cross-contamination issues by eliminating reuse of closed-end cannulas used in these and other surgical procedures. A lubricious coating, which covers both the inside and outside of the cannula, is designed to not only decrease the trauma to the cells inside the lumen, but also to increase the ease of manipulation for extraction and re-injection procedures, minimize bruising and shorten recovery periods.

Over several months prior to the "Entrepreneur of the Year" list arrival, the magazine invited business people and entrepreneurs to nominate others or themselves as possible contenders. Approximately one hundred nominations were received. Pilkington was nominated by one of Tulip BioMed's vendors. The nominees were screened by the Inc. editors and those who qualified were added to the Inc. Website for readers to review and vote on.

Readers were given several weeks to review all nominations, assign a numerical rating on a scale of 1-10, and add comments. According to a magazine spokesperson, many hundreds of comments were received and more people voted than commented. At the end of the voting period, the top 13 "Reader Favorites," based on highest numerical ratings for how important or interesting the nominations were, were announced on the site this week: http://www.inc.com/slideshow_INC/slideviewer.cgi?list=eoy20061208&dir=&c...

"It's great to know that Inc.'s readers are concerned about safety in these surgical procedures. We believe we have a great product and I can see from the comments that others are starting to get it, too," said Pilkington. "I am honored to have been chosen as one of the Reader Favorites."

About Tulip BioMed, Inc.

Tulip BioMed, Inc. (PINKSHEETS: TPBD) is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed, Inc. is the exclusive licensee of patented syringe connection devices that use the worldwide recognized Tulip brand name. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information go to: www.tulipbiomed.com. Products are available for sale at www.tulipdisposable.com.

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:
Beth Walsh
Clearpoint Agency, Inc.
Email Contact
858-724-2500